MedTrace Logo

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC

NCT06111807 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 248

Last updated 2025-03-30

No results posted yet for this study

Summary

Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for non small cell lung cancer (NSCLC), the methods used to decide who gets additional post radical (surgery or definite chemo-radiotherapy) treatment are suboptimal. Some patients get too much treatment, while others do not get enough.

There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.

The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.

GUIDE.MRD-03-NSCLC is a part of the GUIDE.MRD project.

Conditions

  • Lung Cancer Stage III

Interventions

DIAGNOSTIC_TEST

ctDNA

ctDNA will be tested retrospectively, no treatment decisions will be made prospectively

Sponsors & Collaborators

  • LungenClinic Grosshansdorf

    collaborator OTHER

  • Centre Hospitalier Universitaire de Nice

    collaborator OTHER

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Mustafa Abdo, MD · LungenClinic Grosshansdorf

  • Paul Hofman, MD, PhD · Centre Hospitalier Universitaire (CHU) de Nice

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-10
Primary Completion
2025-12-01
Completion
2030-07-31

Countries

  • France
  • Germany
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06111807 on ClinicalTrials.gov